Raymond James analyst Steven Seedhouse upgrades Vera Therapeutics (NASDAQ:VERA) from Outperform to Strong Buy and raises the price target from $29 to $37.
Raymond James Upgrades Vera Therapeutics to Strong Buy, Raises Price Target to $37
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.